Cleo Diagnostics Ltd Cash Flow Conversion Efficiency

Latest as of December 2025: -0.189x

Cleo Diagnostics Ltd cash flow conversion efficiency. Based on the latest financial reports, Cleo Diagnostics Ltd (COV) has a cash flow conversion efficiency ratio of -0.189x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$8.83 Million ≈ $6.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cleo Diagnostics Ltd (2023–2025)

Cash flow conversion efficiency of Cleo Diagnostics Ltd from 2023 to 2025. This chart illustrates how Cleo Diagnostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View COV stock price for real-time trading data and today's change.

Cleo Diagnostics Ltd Cash Flow Conversion Ratio Explained

Cleo Diagnostics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cleo Diagnostics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cleo Diagnostics Ltd ranked by their cash flow conversion efficiency. Also see COV market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Colorpak Indonesia Tbk JK:CLPI	0.041x
Legacy Iron Ore Ltd AU:LCY	0.095x
White Horse Bhd KLSE:5009	0.026x
Apexindo Pratama Duta Tbk JK:APEX	0.129x
Sunrise New Energy Co. Ltd NASDAQ:EPOW	-0.678x
Ideal Power Inc NASDAQ:IPWR	-0.274x
ilShinbiobase Co. Ltd KQ:068330	0.006x
Heramed Ltd AU:HMD	-3.359x

Annual Cash Flow Conversion Efficiency for Cleo Diagnostics Ltd (2023–2025)

The table below shows the annual cash flow conversion efficiency of Cleo Diagnostics Ltd from 2023 to 2025. Review Cleo Diagnostics Ltd leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	AU$5.83 Million ≈ $4.13 Million	AU$-2.90 Million ≈ $-2.05 Million	-0.497x	-130.03%
2024-06-30	AU$9.39 Million ≈ $6.65 Million	AU$-2.03 Million ≈ $-1.44 Million	-0.216x	-129.79%
2023-06-30	AU$-943.41K ≈ $-667.52K	AU$-684.47K ≈ $-484.31K	0.726x	--

About Cleo Diagnostics Ltd

AU:COV Australia Medical Devices

Market Cap

$27.60 Million

AU$39.01 Million AUD

Market Cap Rank

#23871 Global

#921 in Australia

Share Price

AU$0.29

Change (1 day)

-5.00%

52-Week Range

AU$0.27 - AU$0.87

All Time High

AU$0.87